Keeper Security Introduces KeeperDB™, Integrating Zero-Trust Database Access into KeeperPAM®
New capability embeds a secure, zero-trust database interface directly into the Keeper Vault, eliminating exposed credentials, unmanaged tools and insecure access... Read more.
ZIM Updates on Withholding Tax Procedures on March 2026 Cash Dividend
HAIFA, Israel, March 19, 2026 /PRNewswire/ — ZIM Integrated Shipping Services Ltd. (NYSE: ZIM) (“ZIM” or the “Company”), a global... Read more.
Yiren Digital Reports Fourth Quarter and Fiscal Year 2025 Financial Results
BEIJING, March 19, 2026 /PRNewswire/ — Yiren Digital Ltd. (NYSE: YRD) (“Yiren Digital” or the “Company”), a leading fintech company... Read more.
CD&R Expands Climate Leadership Program to Europe with Imperial College Business School and Extends Columbia University Partnership in the U.S. for Second Year
European expansion builds on successful inaugural program with Columbia University LONDON, March 19, 2026 /PRNewswire/ — CD&R (the “Firm”)... Read more.
92% of Companies Exposed to Tax & Compliance Risks When Hiring Internationally, Multiplier Report Finds
Survey of 500 global business leaders finds global hiring is accelerating faster than companies can manage compliance NEW YORK, March 19, 2026 /PRNewswire/ —... Read more.
Brii Biosciences Provides Corporate Updates and Reports Full Year 2025 Financial Results
Advancing HBV Functional Cure Toward Key Phase 2b Data Readouts Increasing Discovery Efforts to Drive Long-term Value Creation Strong Cash Position Supporting Strategic... Read more.
3M to create a leading fire and safety business; acquires Madison Fire & Rescue and combines with Scott Safety
3M will form a new joint venture to offer best-in-class safety, fire-rescue, and suppression solutions for firefighters, first responders, and industrial workers... Read more.
Lilly’s triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes
For the primary endpoint, retatrutide lowered A1C by an average of 1.7% to 2.0% across doses at 40 weeks in TRANSCEND-T2D-1 Participants taking retatrutide 12 mg... Read more.
Lumito and Tethis complete proof-of-concept study demonstrating compatibility between Lumito’s UCNP imaging and Tethis’ SmartBioSurface® slides
LUND, Sweden and MILAN, March 19, 2026 /PRNewswire/ — Lumito AB (“Lumito”) and Tethis S.p.A. (“Tethis”) today announce the completion... Read more.
Cardinal Infrastructure Group Inc. Announces Full Year 2025 Results and Affirms 2026 Guidance
RALEIGH, N.C., March 19, 2026 /PRNewswire/ — Cardinal Infrastructure Group Inc. (NASDAQ: CDNL) (“Cardinal” or the “Company”), today... Read more.